Procter & Gamble Health Ltd
₹ 6,368
-1.54%
10 Sep
12:04 p.m.
About
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
Key Points
- Market Cap ₹ 10,570 Cr.
- Current Price ₹ 6,368
- High / Low ₹ 6,739 / 4,863
- Stock P/E 35.2
- Book Value ₹ 323
- Dividend Yield 1.97 %
- ROCE 47.8 %
- ROE 36.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.0%
- Company has been maintaining a healthy dividend payout of 67.5%
Cons
- Stock is trading at 19.7 times its book value
- The company has delivered a poor sales growth of 0.16% over past five years.
- Debtor days have increased from 39.5 to 56.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 16m | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,273 | |
809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 864 | |
Operating Profit | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 409 |
OPM % | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 32% |
20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 14 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
Depreciation | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 22 |
Profit before tax | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 400 |
Tax % | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | |
43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 301 | |
EPS in Rs | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 181.09 |
Dividend Payout % | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 0% |
3 Years: | -3% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 8% |
3 Years: | 10% |
TTM: | 43% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 6% |
3 Years: | 15% |
1 Year: | 23% |
Return on Equity | |
---|---|
10 Years: | 28% |
5 Years: | 27% |
3 Years: | 33% |
Last Year: | 36% |
Balance Sheet
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
Reserves | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | |
154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | |
Total Liabilities | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 |
110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | |
CWIP | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 |
Investments | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | |
Total Assets | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 |
Cash Flows
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | ||
11 | -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | ||
-17 | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | ||
Net Cash Flow | -1 | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 |
Ratios
Figures in Rs. Crores
Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 |
Inventory Days | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 |
Days Payable | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 |
Cash Conversion Cycle | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 |
Working Capital Days | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 |
ROCE % | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
1d - Dr. Sachin Pawar, Medical Leader, resigning effective September 30, 2025; leaving to pursue other interests.
-
Change In Senior Management Personnel Of The Company
1 Sep - Ketan Kotadiya appointed Head—Medical, Regulatory & R&D at Procter & Gamble Health Limited, effective September 1, 2025.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 29 Aug
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Aug - 58th AGM (29 Aug 2025): dividend approved, Seema Sambasivan reappointed, secretarial auditor appointed effective Apr 1, 2025.
-
Intimation Regarding IEPF''s 100 Days Campaign - 'Saksham Niveshak
26 Aug - 100-day 'Saksham Niveshak' campaign urging claims for unpaid dividends FY2017-18 to FY2024-25.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
Concalls
-
Jun 2025Transcript PPT
-
Dec 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. [1]